Breaking News, Promotions & Moves

Albany Molecular Research, Inc.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Albany Molecular Research, Inc. has named Jonathan D. Evans as vice president of pharmaceutical development and manufacturing. In this newly created position, Mr. Evans will assume responsibility for AMRI’s Chemical Development, Small Scale cGMP Manufacturing, Analytical, Quality Control Quality Assurance, and Large Scale Commercial Manufacturing business components, including operations in both Albany and Syracuse, NY; Hyderabad, India; as well as AMRI’s Large Scale Manufacturing facility in Rensselaer, NY. In addition, he will serve as a key advisor to AMRI chairman, president and chief executive officer Thomas E. D’Ambra, Ph.D., and as a member of the company’s senior leadership team.

Mr. Evans brings 16 years of experience in operations and management, including 13 years at General Electric’s Advanced Materials Division, where he served in a variety of roles, including operations manager, global business manager for the elastomers / specialty sealants business, and general manager of specialty operations, leading GE plants in North and South America. Most recently, he served as general manager of elastomers / specialty polymers, where he led an international team responsible for global business development and global marketing.

“We are pleased to announce the addition of Jonathan Evans to AMRI’s senior leadership team,” said Dr. D’Ambra. “Jon has compiled an exceptional track record at General Electric, and we expect him to play a key leadership role in the ongoing restructuring of our Large Scale Manufacturing operations. His background includes technical, engineering expertise coupled with business acumen and experience in a wide range of business functions, from manufacturing operations to business development. His prior roles integrating corporate acquisitions and reengineering supply chain operations at GE will be key skill sets as we continue to improve operational efficiency, customer service and bottom-line performance.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters